ClearPoint Neuro Inc. - Common Stock (CLPT)
14.70
+0.41 (2.87%)
NASDAQ · Last Trade: Apr 26th, 2:53 PM EDT
Detailed Quote
Previous Close | 14.29 |
---|---|
Open | 14.34 |
Bid | 13.77 |
Ask | 15.80 |
Day's Range | 14.24 - 15.56 |
52 Week Range | 5.105 - 19.22 |
Volume | 326,337 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 270,475 |
Chart
About ClearPoint Neuro Inc. - Common Stock (CLPT)
Clearpoint Neuro Inc is a healthcare technology company focused on transforming the field of neurosurgery through innovative medical devices and advanced imaging solutions. The company develops and commercializes integrated systems that assist neurosurgeons in the precise delivery of therapies to the brain. Their flagship products enhance the surgical process for conditions such as brain tumors and neurological disorders, improving patient outcomes while enabling greater accuracy and efficiency in procedures. Clearpoint Neuro aims to advance the treatment of complex neurological conditions by providing tools that facilitate minimally invasive interventions and enhance the surgeon's capabilities in the operating room. Read More
News & Press Releases
SOLANA BEACH, CA / ACCESS Newswire / April 25, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2025 first quarter on Tuesday, May 13th, after the market close.
Via ACCESS Newswire · April 25, 2025
The platform will be showcased at the American Academy of Neurological Surgeons Annual Meeting in Boston on April 25-28, 2025.
Via ACCESS Newswire · April 24, 2025
Via Benzinga · April 17, 2025

Achieved Record Revenue for 2024 and Growth of 31%;
Via ACCESS Newswire · February 26, 2025

SOLANA BEACH, CA / ACCESS Newswire / February 14, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 fourth quarter and full year on Wednesday, February 26th, after the market close.
Via ACCESS Newswire · February 14, 2025

Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United States
Via ACCESSWIRE · November 13, 2024

Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million
Via ACCESSWIRE · November 7, 2024

President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast Today
Via ACCESSWIRE · October 31, 2024

SOLANA BEACH, CA / ACCESS Newswire / February 12, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced receipt of European Medical Device Regulation (EU MDR) approval for the SmartFlow Neuro Cannula.
Via ACCESS Newswire · February 12, 2025

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 27, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received 510(k) clearance for its ClearPoint Navigation Software Version 3.0.
Via ACCESS Newswire · January 27, 2025

Via Benzinga · October 18, 2024

Via Benzinga · August 27, 2024

CLPT stock results show that ClearPoint Neuro beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 7, 2024

With the number of U.S. citizens aged 65 and above growing to 55.8 million, we could see brain-computer interface stocks accelerate.
Via InvestorPlace · July 27, 2024

These top growth stocks across various sectors have the potential to deliver 5X returns in just five years.
Via InvestorPlace · July 17, 2024

CLPT stock results show that ClearPoint Neuro beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 7, 2024

These penny stocks offer robust operational opportunities amid wider economic and market concerns pushing weaker companies downward.
Via InvestorPlace · May 1, 2024

MedTech stocks are often overlooked despite the inherent healthcare growth trajectory and industry-wide innovative spirit.
Via InvestorPlace · April 11, 2024

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter.
Via Benzinga · March 12, 2024

These under-$15 stocks to buy are one of the few deals remaining in today's economic environment. Don't miss out.
Via InvestorPlace · March 7, 2024

Via Benzinga · February 29, 2024

Via Benzinga · February 28, 2024